Nanobiotix (NASDAQ:NBTX) Shares Down 5.2% - Time to Sell?

Key Points

• Nanobiotix's stock experienced a decline of 5.2%, trading at $8.53, down from a previous close of $9.00, with a notable trading volume increase of 47%.
• Institutional investors and hedge funds currently own 38.81% of Nanobiotix's stock, with new positions acquired by firms like Geode Capital and Jane Street Group.
• The company is focused on developing nanotechnology-based treatments for various cancers, with its lead product candidate being NBTXR3.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s stock price was down 5.2% on Wednesday . The company traded as low as $8.20 and last traded at $8.53. Approximately 19,089 shares traded hands during mid-day trading, an increase of 47% from the average daily volume of 13,015 shares. The stock had previously closed at $9.00.

Nanobiotix Price Performance

The stock has a 50-day moving average of $6.11 and a two-hundred day moving average of $4.52.

Institutional Trading of Nanobiotix

A number of hedge funds have recently bought and sold shares of the company. Millennium Management LLC bought a new stake in Nanobiotix in the 4th quarter worth approximately $39,000. Jane Street Group LLC bought a new stake in Nanobiotix in the 4th quarter worth approximately $73,000. Finally, Geode Capital Management LLC bought a new stake in Nanobiotix in the 4th quarter worth approximately $29,000. Institutional investors own 38.81% of the company's stock.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.